Under the agreement, Biogen Idec said it will make an upfront cash payment of $75 million and additional contingent value payments of up to $487.5 million based on the achievement of development and approval milestones.
Programs under way at Stromedix complement Biogen Idec’s scientific expertise and advances its research and development efforts in immunology, Biogen Idec said in a press release. Biogen Idec is the world’s largest maker of medicines for multiple sclerosis.
The release included a statement from Michael Gilman, founder and chief executive of Stromedix, who said the transaction has the potential to “accelerate the development” of its early-stage drug candidates.
Privately held Stromedix’s investors include Atlas Venture, New Leaf Venture Partners, Bessemer Venture Partners, Red Abbey Venture Partners, and Frazier Healthcare.